EMEA-001178-PIP01-11-M05

Key facts

Invented name
Stivarga
Active substance
regorafenib
Therapeutic area
Oncology
Decision number
P/0141/2020
PIP number
EMEA-001178-PIP01-11-M05
Pharmaceutical form(s)
  • Film-coated tablet
  • Granules
Condition(s) / indication(s)
Treatment of all conditions contained in the category of malignant neoplasms (except haematopoietic and lymphoid tissue)
Route(s) of administration
Oral use
Contact for public enquiries
Bayer AG
Decision type
PM: decision on the application for modification of an agreed PIP

Decision

Related content

How useful was this page?

Add your rating